Linagliptin-Associated Alopecia and Bullous Pemphigoid

  • Ali Someili Department of Medicine, McMaster University, Hamilton, ON, Canada
  • Mohannad Abu Hilal Department of Medicine, McMaster University, Hamilton, ON, Canada
  • Khalid Azzam Department of Dermatology, McMaster University, Hamilton, ON, Canada

Keywords

Gliptin, drug, bullous pemphigoid

Abstract

Bullous pemphigoid is a chronic autoimmune blistering disease. Recently, several reports suggested dipeptidyl peptidase 4 (DPP-4) inhibitors, also known as gliptins, were a potential cause of drug-induced bullous pemphigoid but not of both bullous pemphigoid and alopecia areata together. Here we describe the case of a 68-year-old man with type 2 diabetes mellitus who developed new onset diffuse alopecia on the scalp with diffuse tense bullae over his body a few months after linagliptin was introduced for better control of his diabetes.
DPP-4 inhibitors are not known to increase the risk of alopecia. To the best of our knowledge, this is the first report of linagliptin-associated alopecia areata and bullous pemphigoid, which may help demonstrate if there are any links between DPP-4 inhibitors and alopecia.

References

  • Meyer N, Misery L. Geoepidemiology considerations of auto-immune pemphigus. Autoimmun Rev 2009;9(5):A379–382.

  • Dănescu S, Chiorean R, Macovei V, Sitaru C, Baican A. Role of physical factors in the pathogenesis of bullous pemphigoid: case report series and a comprehensive review of the published work. J Dermatol 2016;43(2):134–140.

  • Haber R, Fayad AM, Stephan F, Obeid G, Tomb R. Bullous pemphigoid associated with linagliptin treatment. JAMA Dermatol 2016;152(2):224–226.

  • Brick K, Weaver C, Lohse C, Pittelkow M, Lehman J, Camilleri M, et al. Incidence and mortality rates of bullous pemphigoid in Olmsted County, Minnesota, over 6 decades. J Am Acad Dermatol 2014;71(1):92–99.

  • Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris–incidence and mortality in the UK: population based cohort study. BMJ 2008;337(7662):160–163.

  • Zhao CY, Murrell DF. Advances in understanding and managing bullous pemphigoid. F1000Res 2015;4. doi: 10.12688/f1000research.6896.1

  • Aovi FI, Halder SS. A study on the prescribing patterns of dipeptidyl peptidase 4 inhibitors in a multidisciplinary hospital complex Birdem, Bangladesh. IOSR JEF 2016;1(10):10–13.

  • da Silva Júnior WS, de Godoy-Matos AF, Kraemer-Aguiar LG. Dipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis? Biomed Res Int 2015;2015:1–10.

  • Kim S, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis 2016;74(11):1968–1975.

  • Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep 2014;8(1):24–28.

  • Abrahami D, Douros A, Yin H, Hoi Yun Yu O, Renoux C, Bitton A, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:k872.

  • Mendonça FMI, Martín-Gutierrez FJ, Ríos-Martín JJ, Camacho-Martinez F. Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors - one due to linagliptin. Dermatology 2016;232(2):249–253.

  • Sakai A, Shimomura Y, Ansai O, Saito Y, Tomii K, Tsuchida Y, et al. Linagligiptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the mid portion of BP180. Br J Dermatol 2017;176(2):541–543.

  • García M, Aranburu MA, Palacios-Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther 2016;41(3):368–370.

  • Yoshiji S, Murakami T, Harashima SI, Ko R, Kashima R, Yabe D, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.J Diabetes Investig 2018;9(2):445–447.

  • Guliani A, Bishnoi A, Aggarwal D, Parsad D. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes. Postgrad Med J 2018;94(1117):662–663.

  • Takama H, Yoshida M, Izumi K, Yanagishista T, Muto J, Ohshima Y, et al. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: recurrence with epitope spreading. Acta Derm Venereol 2018;98(10):983–984.

  • Maki N, Nishie W, Takazawa M, Kakurai M, Yamada T, Umemoto N, et al. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. J Dermatol 2018;45(5):600–602.

  • Harada M, Yoneda A, Haruyama S, Yabuki K, Honma Y, Hiura M, et al. Bullous pemphigoid associated with the dipeptidyl peptidase-4 inhibitor sitagliptin in a patient with liver cirrhosis complicated with rapidly progressive hepatocellular carcinoma. Intern Med 2017;56(18):2471–2474.

  • Esposito I, Moretta G, Peris K, De Simone C. Linagliptin-induced bullous pemphigoid. Int J Dermatol 2017;56(12):1467–1469.

  • Keseroglu HO, Taş-Aygar G, Gönül M, Gököz O, Ersoy-Evans S. A case of bullous pemphigoid ınduced by vildagliptin. Cutan Ocul Toxicol 2017;36(2):201–202.

  • Béné J, Jacobsoone A, Coupe P, Auffret M, Babai S, Hillaire-Buys D, et al. Bullous pemphigoid induced by vildagliptin: a report of three cases. Fundam Clin Pharmacol 2015;29(1):112–114.

  • Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol 2013;149(2):243–244.

  • Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 2011;34(8):e133–e133.
  • Published: 2019-09-10

    Issue: LATEST ONLINE (view)

    Section: Articles

    How to cite:
    Someili, A., Abu Hilal, M., & Azzam, K. (2019). Linagliptin-Associated Alopecia and Bullous Pemphigoid. European Journal of Case Reports in Internal Medicine, 2. https://doi.org/https://doi.org/10.12890/2019_001207